Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?

Damodaran, Shivashankar; Kyriakopoulos, Christos E; Jarrard, David F

Damodaran, Shivashankar; Kyriakopoulos, Christos E; Jarrard, David F.

Afiliação

Damodaran S; Urologic Oncology, Department of Urology, University of Wisconsin School of Medicine and Public Health, 1111 Highland Avenue, Madison, WI 53705-2281, USA.
Kyriakopoulos CE; Department of Medicine, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792-0001, USA.
Jarrard DF; Department of Urology, University of Wisconsin School of Medicine and Public Health, Uiniversity of Wisconsin Carbone Cancer Center, 600 Highland Avenue, Madison, WI 53705, USA. Electronic address: jarrard@urology.wisc.edu.

Urol Clin North Am ; 44(4): 611-621, 2017 Nov.

Article em En | MEDLINE | ID: mdl-29107277

Assuntos

Antineoplásicos Hormonais/uso terapêutico; Neoplasias da Próstata/diagnóstico; Humanos; Masculino; Metástase Neoplásica; Neoplasias da Próstata/tratamento farmacológico; Neoplasias da Próstata/secundário

Palavras-chave

Androgen axis inhibitors; Androgen deprivation therapy (ADT); Docetaxel; Hormone-sensitive prostate cancer (HSPC); Prostate cancer (PCa)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antineoplásicos Hormonais Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans / Male Idioma: En Revista: Urol Clin North Am Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google